Translating genetic insights into medicines

Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. Advances in these areas have enabled Maze and its founders to decode the mysteries of genetic modifiers in a range of severe diseases, which the company aims to turn into medicines that mimic protective modifiers. Maze has assembled a world-class team needed in order to realize this vision, including creative scientific pioneers in genetics, experienced company builders, and biotech industry leaders.

Year Invested: 2019

Recent News

February 28, 2019
Maze Therapeutics Launches with $191 Million to Focus on Translating Genetic Insights into New Medicines

Read More News

Associated Team Members

Charles Homcy, M.D.

Jason Coloma, Ph.D.
Venture Partner

Jeffrey Finer, M.D., Ph.D.
Venture Partner

Eric Green, M.D., Ph.D.

Jeffrey Tong, Ph.D.